First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics
Szeto HH. British Journal of Pharmacology 2014;171:2029-2050.
What it found
Describes how SS-31 binds cardiolipin, stops cytochrome c from acting as a damaging peroxidase, protects mitochondrial structure and supports energy production, and summarises animal studies and early clinical development.
Limitations
Narrative review by the scientist whose laboratory developed the Szeto-Schiller (SS) peptides. Written before the larger human trials, several of which were negative.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.